Aligos Therapeutics, Inc.
ALGS
$10.01
$0.141.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 741.00K | 965.00K | 311.00K | 629.00K | 1.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 741.00K | 965.00K | 311.00K | 629.00K | 1.27M |
| Cost of Revenue | 23.94M | 13.98M | 14.50M | 16.03M | 16.77M |
| Gross Profit | -23.20M | -13.01M | -14.19M | -15.40M | -15.51M |
| SG&A Expenses | 5.17M | 5.56M | 5.05M | 5.16M | 4.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.10M | 19.53M | 19.55M | 21.19M | 21.40M |
| Operating Income | -28.36M | -18.57M | -19.24M | -20.56M | -20.13M |
| Income Before Tax | -31.48M | -15.68M | 43.13M | -82.12M | -19.17M |
| Income Tax Expenses | 56.00K | 185.00K | 43.00K | 27.00K | 91.00K |
| Earnings from Continuing Operations | -31.54M | -15.86M | 43.09M | -82.15M | -19.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.54M | -15.86M | 43.09M | -82.15M | -19.26M |
| EBIT | -28.36M | -18.57M | -19.24M | -20.56M | -20.13M |
| EBITDA | -28.14M | -18.31M | -19.05M | -20.32M | -19.88M |
| EPS Basic | -3.04 | -1.53 | 5.12 | -13.08 | -3.07 |
| Normalized Basic EPS | -1.90 | -0.95 | 3.21 | -8.17 | -1.91 |
| EPS Diluted | -3.04 | -1.53 | -2.11 | -13.08 | -3.07 |
| Normalized Diluted EPS | -1.90 | -0.95 | 3.10 | -8.17 | -1.91 |
| Average Basic Shares Outstanding | 10.37M | 10.35M | 8.41M | 6.28M | 6.27M |
| Average Diluted Shares Outstanding | 10.37M | 10.35M | 8.71M | 6.28M | 6.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |